|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000-14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finkel T, Deng CX and Mostoslavsky R:
Recent progress in the biology and physiology of sirtuins. Nature.
460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chalkiadaki A and Guarente L: The
multifaceted functions of sirtuins in cancer. Nat Rev Cancer.
15:608–624. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michishita E, Park JY, Burneskis JM,
Barrett JC and Horikawa I: Evolutionarily conserved and
nonconserved cellular localizations and functions of human SIRT
proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ford E, Voit R, Liszt G, Magin C, Grummt I
and Guarente L: Mammalian Sir2 homolog SIRT7 is an activator of RNA
polymerase I transcription. Genes Dev. 20:1075–1080. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen S, Blank MF, Iyer A, Huang B, Wang L,
Grummt I and Voit R: SIRT7-dependent deacetylation of the U3-55k
protein controls pre-rRNA processing. Nat Commun. 7:107342016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsai YC, Greco TM and Cristea IM: Sirtuin
7 plays a role in ribosome biogenesis and protein synthesis. Mol
Cell Proteomics. 13:73–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barber MF, Michishita-Kioi E, Xi Y,
Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL,
Chen K, et al: SIRT7 links H3K18 deacetylation to maintenance of
oncogenic transformation. Nature. 487:114–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paredes S, Villanova L and Chua KF:
Molecular pathways: Emerging roles of mammalian Sirtuin SIRT7 in
cancer. Clin Cancer Res. 20:1741–1746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geng Q, Peng H, Chen F, Luo R and Li R:
High expression of Sirt7 served as a predictor of adverse outcome
in breast cancer. Int J Clin Exp Pathol. 8:1938–1945.
2015.PubMed/NCBI
|
|
15
|
de Nigris F, Cerutti J, Morelli C,
Califano D, Chiariotti L, Viglietto G, Santelli G and Fusco A:
Isolation of a SIR-like gene, SIR-T8, that is overexpressed in
thyroid carcinoma cell lines and tissues. Br J Cancer. 86:917–923.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen X, Li P, Xu Y, Chen X, Sun H, Zhao Y,
Liu M and Zhang W: Association of sirtuins with clinicopathological
parameters and overall survival in gastric cancer. Oncotarget.
8:74359–74370. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Sun Z, Chen C, Wang L, Geng Z and
Tao J: Sirtuin7 has an oncogenic potential via promoting the growth
of cholangiocarcinoma cells. Biomed Pharmacother. 100:257–266.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haider R, Massa F, Kaminski L, Clavel S,
Djabari Z, Robert G, Laurent K, Michiels JF, Durand M, Ricci JE, et
al: Sirtuin 7: A new marker of aggressiveness in prostate cancer.
Oncotarget. 8:77309–77316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X and Song Y: MicroRNA-340 inhibits
the growth and invasion of angiosarcoma cells by targeting SIRT7.
Biomed Pharmacother. 103:1061–1068. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kiran S, Oddi V and Ramakrishna G: Sirtuin
7 promotes cellular survival following genomic stress by
attenuation of DNA damage, SAPK activation and p53 response. Exp
Cell Res. 331:123–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang M, Lu X, Zhang C, Du C, Cao L, Hou T,
Li Z, Tu B, Cao Z, Li Y, et al: Downregulation of SIRT7 by
5-fluorouracil induces radiosensitivity in human colorectal cancer.
Theranostics. 7:1346–1359. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu
ML, Hsu CM and Yang MY: Altered expression of SIRT gene family in
head and neck squamous cell carcinoma. Tumour Biol. 34:1847–1854.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McGlynn LM, McCluney S, Jamieson NB,
Thomson J, MacDonald AI, Oien K, Dickson EJ, Carter CR, McKay CJ
and Shiels PG: SIRT3 & SIRT7: Potential novel biomarkers for
determining outcome in pancreatic cancer patients. PLoS One.
10:e01313442015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Zhu D and Qin S: SIRT7 suppresses
the epithelial-to-mesenchymal transition in oral squamous cell
carcinoma metastasis by promoting SMAD4 deacetylation. J Exp Clin
Cancer Res. 37:1482018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang X, Shi L, Xie N, Liu Z, Qian M, Meng
F, Xu Q, Zhou M, Cao X, Zhu WG and Liu B: SIRT7 antagonizes TGF-β
signaling and inhibits breast cancer metastasis. Nat Commun.
8:3182017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi H, Ji Y, Zhang D, Liu Y and Fang P:
MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of
non-small cell lung cancer cells. Oncol Rep. 36:3051–3057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang Y, Han Z, Wang Y and Hao W:
Depletion of SIRT7 sensitizes human non-small cell lung cancer
cells to gemcitabine therapy by inhibiting autophagy. Biochem
Biophys Res Commun. 506:266–271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qian F, Hu Q, Tian Y, Wu J, Li D, Tao M,
Qin L, Shen B and Xie Y: ING4 suppresses hepatocellular carcinoma
via a NF-κB/miR-155/FOXO3a signaling axis. Int J Biol Sci.
15:369–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li L and Bhatia R: The controversial role
of Sirtuins in tumorigenesis-SIRT7 joins the debate. Cell Res.
23:10–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S,
Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell.
170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ciuffreda L, Incani UC, Steelman LS,
Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari
S, Cognetti F, et al: Signaling intermediates (MAPK and PI3K) as
therapeutic targets in NSCLC. Curr Pharm Des. 20:3944–3957. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vakhrusheva O, Smolka C, Gajawada P,
Kostin S, Boettger T, Kubin T, Braun T and Bober E: Sirt7 increases
stress resistance of cardiomyocytes and prevents apoptosis and
inflammatory cardiomyopathy in mice. Circ Res. 102:703–710. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu J, Qin B, Wu F, Qin S, Nowsheen S, Shan
S, Zayas J, Pei H, Lou Z and Wang L: Regulation of serine-threonine
kinase Akt activation by NAD+-dependent deacetylase SIRT7. Cell
Rep. 18:1229–1240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B,
Ji M and Hou P: SIRT7 promotes thyroid tumorigenesis through
phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1
axis. Oncogene. 38:345–359. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Yang L, Tu J, Cai W, Zhang M, Shou
Z, Yao Y and Xu Q: microRNA-526b servers as a prognostic factor and
exhibits tumor suppressive property by targeting Sirtuin 7 in
hepatocellular carcinoma. Oncotarget. 8:87737–87749. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Deng Z, Wang X, Long X, Liu W, Xiang C,
Bao F and Wang D: Sirtuin 7 promotes colorectal carcinoma
proliferation and invasion through the inhibition of E-cadherin.
Exp Ther Med. 15:2333–2342. 2018.PubMed/NCBI
|
|
46
|
Malik S, Villanova L, Tanaka S, Aonuma M,
Roy N, Berber E, Pollack JR, Michishita-Kioi E and Chua KF: SIRT7
inactivation reverses metastatic phenotypes in epithelial and
mesenchymal tumors. Sci Rep. 5:98412015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schlessinger K and Hall A: GSK-3beta sets
Snail's pace. Nat Cell Biol. 6:913–915. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kao SH, Wang WL, Chen CY, Chang YL, Wu YY,
Wang YT, Wang SP, Nesvizhskii AI, Chen YJ, Hong TM and Yang PC:
GSK3β controls epithelial-mesenchymal transition and tumor
metastasis by CHIP-mediated degradation of Slug. Oncogene.
33:3172–3182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhu P, Lv J, Yang Z, Guo L, Zhang L, Li M,
Han W, Chen X, Zhuang H and Lu F: Protocadherin 9 inhibits
epithelial-mesenchymal transition and cell migration through
activating GSK-3β in hepatocellular carcinoma. Biochem Biophys Res
Commun. 452:567–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
